Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ProPhase Labs (PRPH) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for ProPhase Labs (PRPH) over the last 16 years, with Dec 2024 value amounting to $23.9 million.

  • ProPhase Labs' Shares Outstanding (Weighted Average) rose 117.74% to $41.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.5 million, marking a year-over-year increase of 117.74%. This contributed to the annual value of $23.9 million for FY2024, which is 32.30% up from last year.
  • Latest data reveals that ProPhase Labs reported Shares Outstanding (Weighted Average) of $23.9 million as of FY2024, which was up 32.30% from $18.0 million recorded in FY2023.
  • ProPhase Labs' 5-year Shares Outstanding (Weighted Average) high stood at $23.9 million for FY2024, and its period low was $11.6 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $18.0 million (2023), whereas its average is $19.4 million.
  • Data for ProPhase Labs' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 33.67% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows ProPhase Labs' Shares Outstanding (Weighted Average) stood at $11.6 million in 2020, then surged by 33.67% to $15.5 million in 2021, then grew by 4.94% to $16.3 million in 2022, then rose by 10.86% to $18.0 million in 2023, then surged by 32.30% to $23.9 million in 2024.